Janssen | Patient Daily

Janssen

Press release submission | Dec 29, 2021

Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Press release submission | Dec 22, 2021

FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients

Press release submission | Aug 19, 2021

Janssen Presents Phase 1 Results for RYBREVANT™ (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations

Press release submission | May 21, 2021

RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Press release submission | Jan 16, 2019

JANSSEN: Announces European Commission approval of ERLEADA®(apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease

Press release submission | Dec 6, 2018

JANSSEN: DARZALEX® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma

Trending

Patient Daily News Service | Jan 22, 2025

National Pharmacists Group to DOGE: Start search for 'waste and inefficiencies in federal programs' with the pharmacy benefit managers

+ Pharmaceuticals

Patient Daily | Jan 17, 2025

Understanding symptoms and treatment options for long-term effects of COVID-19

Patient Daily News Service | Jan 16, 2025

FTC Chair: Report Finds 'Three Major Pharmacy Benefit Managers Hiked Costs for a Wide Range of Lifesaving Drugs, Including Medications to Treat Heart Disease and Cancer'